Arcellx(ACLX)

REDWOOD CITY, CABiotechnology1 H-1B visas (FY2023)

Focus: Arcellx is a public biotechnology company focused on adaptive immune cell therapies for oncology, headquartered in Redwood City, CA. The company is in early clinical stages with a pipeline centered on engineered T-cell therapies.

Oncology

Profile data last refreshed 15h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Arcellx

AI assessmentNot Hiring

No open roles listed right now. Follow Arcellx to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$110M

Pipeline & Clinical Trials

SPRX002

Acute Myeloid Leukemia

Phase 1

Clinical Trials (1)

NCT05457010Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS

Phase 1

Help build intelligence for Arcellx

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage pipeline in high-growth adaptive immune cell therapy space with multiple Phase 1/2 programs offering ground-floor opportunities
121% R&D intensity indicates deep commitment to innovation and scientific advancement over near-term commercialization
Public company status provides liquidity and potential equity upside while maintaining biotech culture and mission focus

Watch Out For

Significant cash burn ($71M net loss in FY2025) against modest $106M cash position suggests limited runway of ~18 months at current burn rate
Currently zero active job openings signals hiring freeze or restructuring despite public status; all programs remain in Phase 1/2 with no near-term revenue catalysts

Generated by Claude from Arcellx's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

ARC-T Cells

Acute Myeloid Leukemia

Phase 1

anitocabtagene-autoleucel

Relapsed and Refractory Multiple Myeloma

Phase 1

Clinical Trials (1)

NCT04155749Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

Phase 1

anitocabtagene autoleucel

Autoimmune

Phase 1

Clinical Trials (2)

NCT06413498A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

Phase 3

NCT06626919A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

Phase 1

anitocabtagene-autoleucel

Multiple Myeloma

Phase 2

Clinical Trials (1)

NCT05396885Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 5 clinical trials

Top TAs: Oncology, Immunology, Neurology

H-1B (2023): 1 approval

SEC Filings: 2 available

Therapeutic Area Focus

Oncology

4 pipeline

Immunology

1 pipeline

Neurology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$110M0%

R&D Spend

$134M(121%)11%

Net Income

-$71M

Cash

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo